Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:
Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:
- Controlled Release Drug Delivery Market Opportunity: > 90 Billion By 2028
- Global & Regional Market Forecast Till 2028
- Controlled Release Drug Clinical Pipeline Insight By Phase, Indication, Company, Country & Drug Class
- Comprehensive Clinical insight On More Than 200 Drug in Clinical Trials
- Comprehensive Clinical insight On More Than 150 Drug Available in market
- Drug Pricing, Patent & Dosage Insight By indication: Alzheimer’s, Parkinson’s, Schizophrenia , Chronic Pain, Multiple Sclerosis, Diabetes Mellitus, Hypertension & Angina Pectoris
The oral route of medication has been used in clinical applications ever since one can remember. However the surge of the drug’s active component for a brief time after administration has been seen to cause discomfort to patients, giving rise to adverse effects. The thought of delivering the drug in a controlled manner, whether immediate, extended or delayed, stemmed from the idea of providing the drug in a dosage most suitable for the indication. This idea has translated into the development pipelines of several companies, with many of them now working on controlled release drugs.
At present controlled released drugs are available for a number of indications such as diabetes, chronic pain and neurological pain. Additionally, many drugs which were introduced in the market as oral tablets were later joined by their extended release versions which were aimed at providing its therapeutic effects for an extended time. For instance, both Razadyne and Namenda were first approved as oral tablets but were soon followed by their extended release capsules. Both drugs are used for managing the symptoms of Alzheimer’s and are widely used among the patients. Similarly, Bydureon and Tecfidera are extended release tablets used in diabetes and multiple sclerosis respectively. The market for controlled released drugs has grown considerably in the past few years because of the developments and improvements happening lately in the materials being used to create these versions for a controlled release of the active substance.
Some of these drugs come with a coating that slowly dissolves, releasing the drug at low concentrations continuously; another method used is the transdermal route of delivery through which the drug slowly penetrates the skin thus also protecting it from getting eliminated by the digestive system. Currently more than 2500 clinical trials are going on assessing the effects of releasing certain drugs in a controlled manner. One of them is SEP-4199 CR, an investigation drug under development by Sunovion for patients with Bipolar disorders and depression. The study which has enrolled 355 participants began in March, 2022 and is estimated to complete in 2029. The study, currently in phase III, consists of a 12-month open-label flexible-dose treatment period, and a safety follow-up period for evaluating the effects of the drug in a timely manner.
China-based Luye Pharma also has a study underway to test the safety, tolerability and pharmacokinetics of its investigational LPM3770164 sustained-release tablets in patients with Huntington Disease and Tardive Dyskinesia. LPM3770164 is an investigational next generation VMAT2 inhibitor which has entered phase I clinical trial in both the US and China. The clinical trial was initiated in February, 2022 as a dose-escalation study and is estimated to end in July, 2023. The clinical landscape is populated with controlled release drugs not being bent towards one or two major indications but covers a variety of indications like obesity, chronic pain, substance use disorder and a number of genetic disorders.
The crowded pipeline has pushed out some drugs to get regulatory approval. Very recently, Alembic Pharma was given the FDA green light for its Nifedipine extended-release tablets targeted for patients with vasospastic angina, chronic stable angina and hypertension. Other than this, Amneal Pharmaceuticals recently submitted an NDA application for IPX203, indicated for the treatment of Parkinson disease. IPX203 is a novel extended-release formulation of carbidopa/levodopa. The NDA approval was based on data from the company’s RISE-PD trial which was conducted to evaluate the efficacy and safety of IPX203 extended-release capsules in comparison to its immediate-release formulation.
As controlled release drugs have been showing important market milestones in the recent years, the mechanism of drug release have seen a shift too. Several controlled release version of older drugs have been demonstrating good commercial results which has sped up the development of more drugs of these types. To fulfill the purpose, a number of modifications have been made too to ensure a safe concentration of the drug is maintained at all times in the body. Soleno Therapeutics, Overseas Pharmaceuticals, Amneal and Shanghai WD Pharmaceutical are some key pharmaceutical companies with controlled release drugs in development. The pipeline is expected to continue growing because of the presence of several favorable market factors.
Contact:
Neeraj Chawla
Kuick Research
Research Head
neeraj@kuickresearch.com
+91-9810410366